Evidence map›Paper›PMID 34291109›Full record

ArticleERJ open research2021

Reduced neutrophil elastase inhibitor elafin and elevated transforming growth factor-β

Jan C Thomassen, Tobias Trojan, Maxine Walz, Christina Vohlen, Gregor Fink, Ernst Rietschel, Miguel A Alejandre Alcazar, Silke van Koningsbruggen-Rietschel

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05752019 (TAAI Erasmus Research Initiative to Fight CF), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05752019 completednot on this mapstarted 2022, after this paper: background citation

TAAI Erasmus Research Initiative to Fight CF: Monitoring Inflammation in CF Lung Disease Into a New Era

TypeobservationalSponsorErasmus Medical CenterRan2022 to 2024Enrolled103ConditionsCystic Fibrosis, Lung Inflammation, Lung Infection, Lung Disease
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Biomarkers in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  3. Review
  4. Furin as a therapeutic target in cystic fibrosis airways disease.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  5. Article
  6. The effect of TGF-βBMC pulmonary medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jan C ThomassenCF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
Tobias TrojanCF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
Maxine WalzCF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
Christina VohlenTranslational Experimental Pediatrics - Experimental Pulmonology, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
Gregor FinkTranslational Experimental Pediatrics - Experimental Pulmonology, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
Ernst RietschelCF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
Miguel A Alejandre AlcazarCF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
Silke van Koningsbruggen-RietschelCF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.
University of Cologne · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

research questionPulmonary disease progression in patients with cystic fibrosis (CF) is characterised by inflammation and fibrosis and aggravated by

methodsTransforming growth factor-β

resultsOur results demonstrated the following: 1) NE was markedly increased in Pa-positive sputum, whereas elafin was significantly decreased; 2) increased IL-1β/IL-8 levels were associated with both Pa infection and reduced forced expiratory volume in 1 s, and sputum TGF-β

conclusionOur study links Pa infection to an imbalance of NE and NE inhibitor elafin and increased inflammatory mediators. Moreover, our data demonstrate an association between high TGF-β

Identifiers

PMID34291109
PMCPMC8287132
OpenAlexW3164122977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.